EN DE
Watch InflaRx N.V. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

InflaRx N.V. (IFRX) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of InflaRx N.V. stock $0.51, price $1.18, that is 56.8% below the price, quality 25 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in Germany · ISIN NL0012661870

IN InflaRx N.V. logo Thin data Nov 17, 2026

InflaRx N.V.

IFRX · US

Far too expensive (fair value 57% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Revenue last quarter 81% below a year ago. 
Fair value $0.5100 · Strongly overvalued 
Quality 25/100 
Weak Growth (revenue YoY −82.3 %/yr in EUR) 
Negative free cash flow 
Trails peers (1/7) 
Narrow moat 6/100 · thin data
Thin data 
Estimate
Watch InflaRx N.V. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$6.10 $0.7305 Fair Value $0.5100 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range $0.7305 – $6.10 · fair‑value band $0.3800 – $0.6400 · the $1.18 price screens above the $0.5100 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow InflaRx in your weekly email

Every Wednesday you see whether InflaRx is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.

Show moreShow less

Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications.

It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017.

The company was founded in 2007 and is headquartered in Jena, Germany.

Stock analysis

InflaRx N.V. (IFRX) currently trades at $1.18, while our estimate is $0.5100, 57% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.3800 (bear) to $0.6400 (bull), the price of $1.18 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

InflaRx N.V. reported revenue of €29.3K in FY2025 versus €0 in FY2021. Reported net income was −€45.6M in FY2025.

Key figures

Market cap $182M Micro · EPS (TTM) $−0.3700 · Return on equity −38.5% · Return on assets (EBIT) −52.7% (5-year average) · Operating margin 352,965% · Revenue (TTM) −$10.1K · Revenue growth (YoY) −80.8% · Free cash flow −€34.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 57% below its 52-week high and 43% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −57%, IFRX screens richer than that median.

Fair Value

Bear $0.3800 Fair Value $0.5100 Bull $0.6400
Price $1.18 · Downside -56.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 25/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 10
Are margins and returns getting better?
Cashflow 5
Do the profits arrive as real cash?
Financial strength 74
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 12
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 22
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
Revenue growth 1 year
−82.3%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−22.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−8,417.7% (2017) → −164,525.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

IFRX screens overvalued: fair value 57% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare InflaRx N.V. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 25 · Bottom 25%
Fair Value upside −56.8% · Bottom 25%
Profitability
Return on assets −82.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −80.8% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.39× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 1
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs IFRX
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs IFRX
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs IFRX
argenx SE ARGX $950.95 $908.40 −4% vs IFRX
CSL Limited CSL A$199.55 A$186.49 −7% vs IFRX
Moderna, Inc MRNA $215.27 $135.64 −37% vs IFRX
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs IFRX
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs IFRX
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs IFRX
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs IFRX

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

InflaRx N.V.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "InflaRx N.V. Fair Value". https://www.fairvalue-calculator.com/stock/IFRX

Frequently asked questions

Is InflaRx N.V. (IFRX) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $0.5100 versus a price of $1.18, about 57% lower (overvalued).
What is the fair value of IFRX?
Our estimate for InflaRx N.V. is $0.5100 (as of Nov 17, 2026), built from audited fundamentals. The current price: $1.18.
What is the quality score of IFRX?
InflaRx N.V. has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for InflaRx N.V. (IFRX)?
Our calculated price target is the estimate of $0.5100 (as of Nov 17, 2026). Cautious scenario $0.3800, optimistic scenario $0.6400. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the InflaRx N.V. stock forecast for 2026?
Our estimate puts fair value at $0.5100, about 57% lower versus a price of $1.18 (overvalued). Cautious scenario $0.3800, optimistic scenario $0.6400. The calculation is refreshed regularly with new filings.
What is the intrinsic value of InflaRx N.V. (IFRX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For InflaRx N.V. it is $0.5100 per share (as of Nov 17, 2026), against a price of $1.18.
Is InflaRx N.V. stock overvalued or undervalued in 2026?
As of Nov 17, 2026, IFRX trades above its calculated fair value: price $1.18, fair value $0.5100, a gap of about −57% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IFRX?
No. The price is what the market pays today ($1.18); the fair value is what the company's own numbers justify ($0.5100). For InflaRx N.V. the two are $0.6700 per share apart. That gap is exactly why we show both numbers side by side.
How much is InflaRx N.V. worth?
The market values InflaRx N.V. at about $182M (market capitalisation, as of Nov 17, 2026). Per share that is $1.18; our models calculate a fair value of $0.5100 per share.
What do the bullish and bearish scenarios say about IFRX?
Our models span a range for InflaRx N.V.: cautious scenario $0.3800, base $0.5100, optimistic $0.6400 per share (as of Nov 17, 2026, price $1.18). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of InflaRx N.V. (IFRX)?
Balance-sheet figures for InflaRx N.V. (as of Nov 17, 2026): return on equity −38.5%. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is IFRX from its 52-week high?
InflaRx N.V. trades at $1.18, about 57% below its 52-week high of $2.74 and 43% above the low of $0.8254 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $0.5100 is for.
Which stocks are comparable to InflaRx N.V.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is InflaRx N.V. stock attractive at the current price?
The data as of Nov 17, 2026: price $1.18, calculated fair value $0.5100 (−57%), Quality Score 25/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. InflaRx N.V. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of InflaRx N.V. (IFRX)?
The closing price on Nov 16, 2026 was $1.18. Our estimate is $0.5100, about 57% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with InflaRx N.V. right now?
The price sits above even our optimistic bull case ($0.6400). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of InflaRx N.V.

How large is the market capitalisation of InflaRx N.V. (IFRX)?
The market capitalisation of InflaRx N.V. is $182M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of InflaRx N.V. (IFRX)?
Earnings per share at InflaRx N.V. are $−0.3700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of InflaRx N.V. (IFRX)?
The return on equity (ROE) of InflaRx N.V. is −38.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of InflaRx N.V. (IFRX)?
On an EBIT basis the return on assets of InflaRx N.V. is −52.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of InflaRx N.V. (IFRX)?
The operating margin of InflaRx N.V. is 352,965% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much revenue does InflaRx N.V. (IFRX) generate?
InflaRx N.V. generates revenue of −$10.1K (last twelve months). Revenue of the last twelve months (TTM), the most recent full year, not the calendar year.
How fast is revenue growing at InflaRx N.V. (IFRX)?
Revenue at InflaRx N.V. is down 80.8% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does InflaRx N.V. (IFRX) generate?
The free cash flow of InflaRx N.V. is −€34.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does InflaRx N.V. (IFRX) hold?
InflaRx N.V. holds more cash than debt, €15.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch InflaRx N.V. in the live analysis

One click puts InflaRx N.V. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.